UNSPSC 51181629: Levothyroxine sodium

This classification denotes a thyroid hormone with the molecular formula C15H10I4NO4.Na.H2O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 9J765S329G, chemically known as 3,5,3,5-tetraiodothyronine but more generally known as levothyroxine sodium, which bears U.S. National Institutes of Health Compound Identifier 853. European Medicines Agency schedules Levothyroxine sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08495MIG.

World Health Organization schedules levothyroxine sodium in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.

UNSPSC 51181629 Levothyroxine sodium, a Commodity code, nominally encompasses thyroid-replacement pharmaceuticals; however, the recent state and local opportunities tagged under this code show a stark mismatch between the code's intended scope and actual procurement activity. The two most recent solicitations involve water-treatment chemicals (sodium hypochlorite and sulfuric acid) and a multi-source generic pharmaceutical cooperative purchasing framework, neither of which directly relates to levothyroxine sodium specifically. The code shows little relevant recent activity tied to its stated commodity.

The County of Orange, California, issued an IFB (solicitation 0803008401RE) due March 27, 2026, for chemicals to support water treatment operations on a five-year contract with DOT, OSHA, and EPA compliance requirements; bidders receive a five percent preference if certified as Orange County Local Small Businesses, or eight percent if certified as both OCLSB and Disabled Veteran Business Enterprises. Separately, the Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP (S1070000015802) due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon, with pricing weighted at 75 percent and compliance with cGMP and Drug Supply Chain Security Act requirements mandatory. The mismatch suggests this Commodity code may be incorrectly applied in state procurement systems or that the underlying data reflects data-entry errors rather than genuine levothyroxine sodium procurement activity by state and local governments.